You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Yahoo FinanceMay 22
Aeglea Biotherapeutics Inc President & CEO Anthony G. Quinn Bought $180,028 of Shares
- By insider President & CEO of Aeglea Biotherapeutics Inc (AGLE) Anthony G. Quinn bought 26,592 shares of AGLE on 05/22/2019 at an average price of $6.77 a share. The total cost of this purchase was $180,028. Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer. Aeglea BioTherapeutics Inc has a market cap of $197.610 milli...
Associated PressMay 7
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D on Track for First Patient Dosing During 2Q19 AUSTIN, Texas, May 07, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers nex...
Expected Aug 8, Pre-Market